Literature DB >> 32997362

Restoration of circPSMC3 sensitizes gefitinib-resistant esophageal squamous cell carcinoma cells to gefitinib by regulating miR-10a-5p/PTEN axis.

Han Zhu1, Fang Du2, Chenghua Cao3.   

Abstract

Circular RNAs (circRNAs) has been shown to play an important role in the progression of various cancers. However, the function and underlying mechanisms of circRNAs affecting chemotherapy resistance in esophageal squamous cell carcinoma (ESCC) remain largely unknown. In this study, we used gefitinib-resistant (GR) ESCC cells to investigate the function of circPSMC3 and clarify the underlying mechanism in chemotherapy resistance in ESCC. The results suggested that circPSMC3 expression was downregulated, but miR-10a-5p was upregulated in ESCC tissues and cells, as well as in GR ESCC cells. CircPSMC3 overexpression increased the sensitivity of ESCC cells to gefitinib, as indicated by reduced half maximal inhibitory concentration value, increased apoptosis rate and cleaved caspase-3 protein expression. CircPSMC3 directly interacted with miR-10a-5p and inhibited the expression of miR-10a-5p. Phosphatase and tensin homolog (PTEN) was a direct target of miR-10a-5p and circPSMC3 promoted PTEN expression via decreasing miR-10a-5p level. Moreover, the effect of circPSMC3 on resistance of GR ESCC cells to gefitinib was remarkably reduced by restoration of miR-10a-5p and downregultion of PTEN. Taken together, these observations suggested that upregulation of circPSMC3 overcame resistance of GR ESCC cells to gefitinib by modulating the miR-10a-5p/PTEN axis, which provide a new therapeutic strategy for overcoming gefitinib resistance in ESCC.
© 2020 International Federation for Cell Biology.

Entities:  

Keywords:  circular RNA PSMC3; esophageal squamous cell carcinoma; gefitinib microRNA-10a-5p; phosphatase and tensin homolog

Year:  2020        PMID: 32997362     DOI: 10.1002/cbin.11473

Source DB:  PubMed          Journal:  Cell Biol Int        ISSN: 1065-6995            Impact factor:   3.612


  8 in total

Review 1.  Roles of PTEN inactivation and PD-1/PD-L1 activation in esophageal squamous cell carcinoma.

Authors:  Rong Qiu; Wenxi Wang; Juan Li; Yuxiang Wang
Journal:  Mol Biol Rep       Date:  2022-03-17       Impact factor: 2.742

2.  Xprediction: Explainable EGFR-TKIs response prediction based on drug sensitivity specific gene networks.

Authors:  Heewon Park; Rui Yamaguchi; Seiya Imoto; Satoru Miyano
Journal:  PLoS One       Date:  2022-05-18       Impact factor: 3.752

3.  circ_000166/miR-296 Aggravates the Process of Diabetic Renal Fibrosis by Regulating the SGLT2 Signaling Pathway in Renal Tubular Epithelial Cells.

Authors:  Sheng Chen
Journal:  Dis Markers       Date:  2022-05-16       Impact factor: 3.464

Review 4.  Current advances and future perspectives on the functional roles and clinical implications of circular RNAs in esophageal squamous cell carcinoma: more influential than expected.

Authors:  Chenxi Ju; Jing He; Chang Wang; Jinxiu Sheng; Jinlin Jia; Dan Du; Hongle Li; Mingxia Zhou; Fucheng He
Journal:  Biomark Res       Date:  2022-06-07

Review 5.  Advances in the Study of CircRNAs in Tumor Drug Resistance.

Authors:  Song Wang; Long Qian; Tingting Cao; Li Xu; Yan Jin; Hao Hu; Qingsheng Fu; Qian Li; Ye Wang; Jiawei Wang; Yabin Xia; Xiaoxu Huang
Journal:  Front Oncol       Date:  2022-05-09       Impact factor: 5.738

Review 6.  The Role of Circular RNAs in the Drug Resistance of Cancers.

Authors:  Xin-Yuan Liu; Qi Zhang; Jing Guo; Peng Zhang; Hua Liu; Zi-Bin Tian; Cui-Ping Zhang; Xiao-Yu Li
Journal:  Front Oncol       Date:  2022-01-05       Impact factor: 6.244

Review 7.  Biological and clinical implications of metastasis-associated circular RNAs in oesophageal squamous cell carcinoma.

Authors:  Xin Fang; Sachin Mulmi Shrestha; Li-Hua Ren; Rui-Hua Shi
Journal:  FEBS Open Bio       Date:  2021-10-16       Impact factor: 2.693

Review 8.  The Emerging Roles of Circular RNAs in the Chemoresistance of Gastrointestinal Cancer.

Authors:  Man Wang; Fei Yu; Yuan Zhang; Lei Zhang; Wenguang Chang; Kun Wang
Journal:  Front Cell Dev Biol       Date:  2022-01-21
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.